• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

suPAR Surprises as a Biomarker of Invasive Outcomes in Pleural Infection.

作者信息

Idell Steven, Lee Y C Gary

机构信息

Department of Cellular and Molecular BiologyUniversity of Texas Health Science Center at TylerTyler, Texasand.

Sir Charles Gairdner Hospital and University of Western AustraliaPerth, Western Australia, Australia.

出版信息

Am J Respir Crit Care Med. 2020 Jun 15;201(12):1470-1472. doi: 10.1164/rccm.202003-0525ED.

DOI:10.1164/rccm.202003-0525ED
PMID:32176528
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7301739/
Abstract
摘要

相似文献

1
suPAR Surprises as a Biomarker of Invasive Outcomes in Pleural Infection.可溶性尿激酶型纤溶酶原激活物受体作为胸膜感染侵袭性结局生物标志物的惊人发现。
Am J Respir Crit Care Med. 2020 Jun 15;201(12):1470-1472. doi: 10.1164/rccm.202003-0525ED.
2
Pleural Fluid suPAR Levels Predict the Need for Invasive Management in Parapneumonic Effusions.胸腔液中 suPAR 水平可预测类肺炎性胸腔积液患者是否需要有创性治疗。
Am J Respir Crit Care Med. 2020 Jun 15;201(12):1545-1553. doi: 10.1164/rccm.201911-2169OC.
3
Prognostic and diagnostic potential of suPAR levels in pleural effusion.胸腔积液中可溶性尿激酶型纤溶酶原激活物受体水平的预后及诊断潜力
J Infect. 2017 Nov;75(5):465-467. doi: 10.1016/j.jinf.2017.07.002. Epub 2017 Jul 14.
4
Diagnostic value of suPAR in differentiating noncardiac pleural effusions from cardiac pleural effusions.可溶性尿激酶型纤溶酶原激活物受体在鉴别非心源性胸腔积液与心源性胸腔积液中的诊断价值。
Clin Respir J. 2016 Jan;10(1):61-6. doi: 10.1111/crj.12186. Epub 2014 Aug 4.
5
Comparison of soluble urokinase plasminogen activator receptor, soluble triggering receptor expressed on myeloid cells 1, procalcitonin and C-reactive protein in distinguishing concurrent bacterial infection from idiopathic inflammatory myopathy.可溶性尿激酶型纤溶酶原激活物受体、髓系细胞表达的可溶性触发受体1、降钙素原和C反应蛋白在区分特发性炎性肌病并发细菌感染中的比较
Rheumatol Int. 2017 Apr;37(4):585-592. doi: 10.1007/s00296-016-3609-x. Epub 2016 Nov 22.
6
SuPAR in pleural fluid may function as a biological marker for infection in critically ill patients with pleural effusions.
J Infect. 2014 Jun;68(6):607-9. doi: 10.1016/j.jinf.2014.02.005. Epub 2014 Feb 15.
7
SuPAR, an emerging biomarker in kidney and inflammatory diseases.尿可溶性髓系细胞触发受体-1，肾脏病和炎症性疾病的一个新兴生物标志物。
Postgrad Med J. 2018 Sep;94(1115):517-524. doi: 10.1136/postgradmedj-2018-135839. Epub 2018 Sep 3.
8
Serum soluble urokinase-type plasminogen activator receptor as a biological marker of bacterial infection in adults: a systematic review and meta-analysis.血清可溶性尿激酶型纤溶酶原激活物受体作为成人细菌感染的生物学标志物：系统评价和荟萃分析。
Sci Rep. 2016 Dec 19;6:39481. doi: 10.1038/srep39481.
9
The diagnostic value of soluble urokinase-type plasminogen activator receptor (suPAR) for the discrimination of vertebral osteomyelitis and degenerative diseases of the spine.可溶性尿激酶型纤溶酶原激活物受体（suPAR）对鉴别脊椎骨髓炎和脊柱退行性疾病的诊断价值。
J Orthop Surg Res. 2019 Nov 14;14(1):367. doi: 10.1186/s13018-019-1420-6.
10
Expression of Urokinase-type Plasminogen Activator Receptor and its Soluble Form in Type 2 Diabetic Kidney Disease.尿激酶型纤溶酶原激活物受体及其可溶性形式在 2 型糖尿病肾病中的表达。
Arch Med Res. 2019 Jul;50(5):249-256. doi: 10.1016/j.arcmed.2019.08.007. Epub 2019 Oct 5.

引用本文的文献

1
Soluble Urokinase Plasminogen Activator Receptor (SuPAR) Analysis for Diagnosis of Periprosthetic Joint Infection.可溶性尿激酶型纤溶酶原激活物受体（SuPAR）分析在人工关节周围感染诊断中的应用
Antibiotics (Basel). 2024 Feb 12;13(2):179. doi: 10.3390/antibiotics13020179.

本文引用的文献

1
Pleural Fluid suPAR Levels Predict the Need for Invasive Management in Parapneumonic Effusions.胸腔液中 suPAR 水平可预测类肺炎性胸腔积液患者是否需要有创性治疗。
Am J Respir Crit Care Med. 2020 Jun 15;201(12):1545-1553. doi: 10.1164/rccm.201911-2169OC.
2
Phase 1 trial of intrapleural LTI-01; single chain urokinase in complicated parapneumonic effusions or empyema.LTI-01（单链尿激酶）胸腔内给药治疗复杂性类肺炎性胸腔积液或脓胸的 1 期临床试验。
JCI Insight. 2019 Apr 18;5(10):127470. doi: 10.1172/jci.insight.127470.
3
Fibrin turnover and pleural organization: bench to bedside.纤维蛋白转换与胸膜组织：从基础到临床。
Am J Physiol Lung Cell Mol Physiol. 2018 May 1;314(5):L757-L768. doi: 10.1152/ajplung.00501.2017. Epub 2018 Jan 18.
4
Precision-guided, Personalized Intrapleural Fibrinolytic Therapy for Empyema and Complicated Parapneumonic Pleural Effusions: The Case for the Fibrinolytic Potential.精准引导、个性化的胸膜内纤维蛋白溶解疗法治疗脓胸和复杂性肺炎旁胸腔积液：纤维蛋白溶解潜力的实例
Clin Pulm Med. 2017 Jul;24(4):163-169. doi: 10.1097/CPM.0000000000000216.
5
Targeting plasminogen activator inhibitor-1 in tetracycline-induced pleural injury in rabbits.靶向纤溶酶原激活物抑制剂-1 治疗四环素诱导的兔胸膜损伤。
Am J Physiol Lung Cell Mol Physiol. 2018 Jan 1;314(1):L54-L68. doi: 10.1152/ajplung.00579.2016. Epub 2017 Aug 31.
6
Prognostic and diagnostic potential of suPAR levels in pleural effusion.胸腔积液中可溶性尿激酶型纤溶酶原激活物受体水平的预后及诊断潜力
J Infect. 2017 Nov;75(5):465-467. doi: 10.1016/j.jinf.2017.07.002. Epub 2017 Jul 14.
7
Dose dependency of outcomes of intrapleural fibrinolytic therapy in new rabbit empyema models.新兔脓胸模型中胸膜内纤维蛋白溶解疗法疗效的剂量依赖性
Am J Physiol Lung Cell Mol Physiol. 2016 Aug 1;311(2):L389-99. doi: 10.1152/ajplung.00171.2016. Epub 2016 Jun 24.
8
Diagnostic value of suPAR in differentiating noncardiac pleural effusions from cardiac pleural effusions.可溶性尿激酶型纤溶酶原激活物受体在鉴别非心源性胸腔积液与心源性胸腔积液中的诊断价值。
Clin Respir J. 2016 Jan;10(1):61-6. doi: 10.1111/crj.12186. Epub 2014 Aug 4.
9
Overexpression of the urokinase receptor splice variant uPAR-del4/5 in breast cancer cells affects cell adhesion and invasion in a dose-dependent manner and modulates transcription of tumor-associated genes.尿激酶受体剪接变体 uPAR-del4/5 在乳腺癌细胞中的过表达以剂量依赖的方式影响细胞黏附和侵袭，并调节肿瘤相关基因的转录。
Biol Chem. 2012 Dec;393(12):1449-55. doi: 10.1515/hsz-2012-0206.
10
suPAR: the molecular crystal ball.可溶性尿激酶型纤溶酶原激活物受体：分子水晶球
Dis Markers. 2009;27(3):157-72. doi: 10.3233/DMA-2009-0657.